Health Care Market News " Defence Therapeutics (CSE:DTC) begins IND-enabling testing of Its AccuTOX lead compound against breast cancer Defence Therapeutics (DTC) has begun its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited. John Ballem2 mins10 January 2022 08:45 (EDT)
Health Care Market News " Defence Therapeutics (CSE:DTC) Accum variants increases potency of T-Deruxtecan antibody-drug conjugate Defence Therapeutics’ (DTC) is pleased to announce strong in vitro results of its AccumTM variants on the recent Enhertu®ADC owned by AstraZeneca and John Ballem2 mins13 October 2021 09:00 (EDT)
Health Care Market News " Defence Therapeutics (CSE:DTC) is preparing to initiate a Phase I trial for one of its leading AccuTOX candidates against breast cancer Defence Therapeutics (DTC) will be completing all requirements needed to initiate a Phase I trial for one of its leading AccuTOX candidate against John Ballem2 mins29 September 2021 09:00 (EDT)
Health Care " Knight Therapeutics (TSX:GUD) receives Health Canada approval for NERLYNX (Neratinib) Health Canada has approved NERLYNX® (neratinib) for the treatment of metastatic HER2-overexpressed/amplified breast cancer. John Ballem2 mins06 July 2021 09:00 (EDT)
